ArticleProceedings of the National Academy of Sciences of the United States of America2009
Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs.PloS one · 2014Trial
- Genetic and Molecular Characterization of the Immortalized Murine Hepatic Stellate Cell Line GRX.Cells · 2022Article
- Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor.Cell death discovery · 2020Article
- HIV‑1 integrase inhibitors targeting various DDE transposases: Retroviral integration versus RAG‑mediated recombination (Review).Molecular medicine reports · 2019Review
- Article
- Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV.Drugs in context · 2018Review
- Article
- HIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J recombination.Cell death & disease · 2017Article
- Retroviral integrase protein and intasome nucleoprotein complex structures.World journal of biological chemistry · 2017Review
- Histones Are Rapidly Loaded onto Unintegrated Retroviral DNAs Soon after Nuclear Entry.Cell host & microbe · 2016Article
- Two case reports of severe myocarditis associated with the initiation of dolutegravir treatment in HIV patients.Medicine · 2016Article
- Infectivity and insertional mutagenesis of endogenous retrovirus in autoimmune NZB and B/W mice.The Journal of general virology · 2015Article
- A two-week regimen of high-dose integrase inhibitors does not cause nephrotoxicity in mice.Antiviral chemistry & chemotherapy · 2015Article
- Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus.Seminars in immunopathology · 2014Review
- Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents.Journal of virology · 2013Article
- B cell tolerance and positive selection in lupus.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Discovery of drugs that possess activity against feline leukemia virus.The Journal of general virology · 2012Article
- LINE-1 retroelements complexed and inhibited by activation induced cytidine deaminase.PloS one · 2012Article
- An autoimmune disease prevented by anti-retroviral drugs.Retrovirology · 2011Article
- Differential sensitivities of retroviruses to integrase strand transfer inhibitors.Journal of virology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Raltegravir is a recently, Food and Drug Administration-approved, small-molecule drug that inhibits retroviral integrase, thereby preventing HIV DNA from inserting itself into the human genome. We report here that the activity profile of raltegravir on the replication of murine leukemia virus is similar to that for HIV, and that the drug specifically affects autoimmune disease in mice, in which endogenous retroelements are suspected to play a role. While NZW and BALB/c mice, which do not succumb to autoimmune disease, are not affected by raltegravir, lupus-prone (NZBxNZW) F(1) mice die of glomerulonephritis more than a month earlier than untreated mice. Raltegravir-treated NZB mice, which share the H-2 haplotype with BALB/c mice, but which are predisposed to autoimmune hemolytic anemia, develop auto-antibodies to their red blood cells >3 months earlier than untreated mice of the same strain. Because nonautoimmune mice are not affected by raltegravir, we consider off-target effects unlikely and attribute the exacerbation of autoimmunity to the inhibition of retroviral integrase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.